Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lymphoma 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Paraganglioma, Extra-Adrenal 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma 1Gynecological Cancer 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Breast Neoplasm Female 1

Interventions

penpulimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Paraganglioma, Extra-Adrenal × penpulimab × Clear all
NCT05885399 2023-06-02

The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

Peking Union Medical College Hospital

Phase 2 Unknown
5 enrolled
CNSEndocrine

Neoplasm Metastasis, Paraganglioma, Extra-Adrenal, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡